Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation

Presentation #4488/Poster #A0114, ARVO Annual Meeting, Session #: 438, Session Title: Dry eye disease, II, Wednesday, May 6, 2015, 11:00 AM to 12:45 PM PT Presenting and corresponding author: Karen Tubridy, Eleven Biotherapeutics, karen.tubridy@elevenbio.com Purpose: Interleukin-1 (IL-1) is a key mediator of ocular surface inflammation in dry eye disease (DED) and allergic conjunctivitis (AC). IL-1 is important not only in the initiation and maintenance of the inflammatory response, but also in mediating hypersensitization of peripheral nerves. EBI-005 is an IL-1 receptor inhibitor specifically designed and engineered for topical ophthalmic delivery. EBI-005 has been evaluated in several randomized, controlled clinical trials in DED and AC.